Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Muscle Impact of Treating Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Nami Safai Haeri
- Target Recruit Count
- 20
- Registration Number
- NCT05666310
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05655013
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Denosumab vs Zoledronate After Lumbar Fusion
- Conditions
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05638399
- Locations
- 🇨🇳
ShenzhenPH, Shenzhen, Guangdong, China
Denosumab vs Zoledronate After Vertebroplasty
- Conditions
- Interventions
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT05598606
- Locations
- 🇨🇳
ShenzhenPH, Shenzhen, Guangdong, China
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
- Conditions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 20
- Registration Number
- NCT05405894
- Locations
- 🇨🇦
University of Calgary, McCaig Institute for Bone and Joint Health, Calgary, Alberta, Canada
Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 50
- Registration Number
- NCT05164952
- Locations
- 🇪🇬
Clinical Oncology Department, Assuit University Hospital, Asyūţ, Asyut, Egypt
Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 122
- Registration Number
- NCT05106517
- Locations
- 🇨🇳
ShenzhenPH, Shenzhen, Guangdong, China
Romosozumab Use to Build Skeletal Integrity
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Susan L. Greenspan
- Target Recruit Count
- 200
- Registration Number
- NCT05058976
- Locations
- 🇺🇸
UPMC Senior Communities, Pittsburgh, Pennsylvania, United States
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Stinus Gadegaard Hansen
- Target Recruit Count
- 60
- Registration Number
- NCT04742010
- Locations
- 🇩🇰
Hospital South West Jutland, Esbjerg, Denmark
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18028
- Registration Number
- NCT04736693
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.